Clinical Trials Logo

Cholestatic Liver Disease clinical trials

View clinical trials related to Cholestatic Liver Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05922332 Not yet recruiting - Clinical trials for Cholestatic Liver Disease

Application and Effect Evaluation of Medium Chain Fatty Acid Rich Milk Powder in Infants With Cholestatic Liver Disease

Start date: February 2024
Phase: N/A
Study type: Interventional

To verify the effect of feeding milk powder rich in medium chain fatty acids on improving the nutritional status and disease status of infants with cholestatic liver disease and To evaluate the safety of feeding milk powder rich in medium chain fatty acids in infants with cholestatic liver disease.

NCT ID: NCT05045482 Recruiting - Cirrhosis Clinical Trials

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Start date: October 21, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease

NCT ID: NCT04787419 Active, not recruiting - Clinical trials for Cholestatic Liver Disease

Probiotics in Pediatric Chronic Cholestasis

Start date: September 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

double blinded RCT (probiotics vs placebo) given to pediatric patients with chronic cholestasis for 4 weeks duration. baseline characteristics (antropometry, gastrointestinal symptoms, laboratory examinations) would be compared pre vs post treatment

NCT ID: NCT04729751 Active, not recruiting - Alagille Syndrome Clinical Trials

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

RISE
Start date: September 9, 2021
Phase: Phase 2
Study type: Interventional

This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in children <12 months of age with Alagille Syndrome [ALGS] or Progressive Familial Intrahepatic Cholestasis [PFIC].

NCT ID: NCT04168385 Active, not recruiting - Clinical trials for Cholestatic Liver Disease

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study

MERGE
Start date: January 16, 2020
Phase: Phase 2
Study type: Interventional

Evaluate the long-term safety of maralixibat (MRX) in subjects with cholestatic liver disease including, but not limited to, Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC) and Biliary Atresia.

NCT ID: NCT01829698 Completed - Clinical trials for Cholestatic Liver Disease

Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC

Start date: August 2009
Phase: Phase 3
Study type: Interventional

Though ursodeoxycholate acid (UDCA) is the well known effective therapy for PBC,clinical effectiveness of UDCA may be limited by its poor absorption and extensive biotransformation.The more hydrophillic bile acid tauroursodeoxycholate (TUDCA) is the active ingredients of UDCA,and has been approved by state food and drug administration in China for treatment of cholesterol stones.So it is necessary to verify the efficacy and safety of TUDCA in the treatment of adult primary biliary cirrhosis. In this randomized, double-blinded, double -dummy, parallel-controlled and multicenter clinical trial, we detect the proportion of patients who had AKP decline more than 25% as the primary outcome;decline of ALP,total bilirubin, GGT,ALT and AST as secondary outcomes after patients were treated with TUDCA or UDCA for 24 weeks.